```json
{
"content": [
{
"type": "paragraph",
"content": "North America dominates the Polycythemia Vera Treatment Drugs market growth, underpinned by a 95% JAK-inhibitor formulary adoption, favorable orphan-drug reimbursement, and a 35% rise in Medicare-Medicaid dual eligibility that expands high-risk patient pools; regional forecast CAGR of 7.1% through 2030."
},
{
"type": "paragraph",
"content": "Europe maintains the second-largest share, driven by EMA fast-track approvals, cross-border real-world evidence networks, and sustainability-linked procurement that rewards long-term efficacy; Germany and France account for 48% of regional spend."
},
{
"paragraph",
"content": "Asia Pacific is the fastest-growing region (CAGR 9.4%), fueled by China’s 2022 National Reimbursement Drug List expansion, India’s plasma-cytapheresis infrastructure build-outs, and Japan’s aging cohort >65 years expected to double to 37% by 2030."
},
{
"type": "paragraph",
"content": "Latin America benefits from federal biosimilar substitution policies and a 22% YoY increase in private oncology insurance uptake, though FX volatility tempers immediate regional forecast upside."
},
{
"type": "paragraph",
"content": "Middle East & Africa registers double-digit volume demand yet remains price-sensitive; Saudi Vision 2030 life-science PPPs and South Africa’s forthcoming National Health Insurance pilot are catalyzing early-stage Polycythemia Vera Treatment Drugs market growth."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 42 },
{ "name": "Europe", "value": 28 },
{ "name": "Asia Pacific", "value": 19 },
{ "name": "Latin America", "value": 7 },
{ "name": "Middle East & Africa", "value": 4 }
]
}
}
```
